Biopsy Devices Market Size, Share, Growth, and Industry Analysis, By Type (MRI?guided Biopsy,Ultrasound?guided Biopsy,Stereotactic?guided Biopsy), By Application (Diagnostic & Imaging Centers,Hospitals,Others), Regional Insights and Forecast to 2035

Biopsy Devices Market Overview

The global Biopsy Devices Market is forecast to expand from USD 2333.96 million in 2026 to USD 2486.14 million in 2027, and is expected to reach USD 4121.47 million by 2035, growing at a CAGR of 6.52% over the forecast period.

The Biopsy Devices Market comprises devices and systems used for sampling tissue or cells from organs for diagnostic evaluation. It includes imaging-guided systems (MRI-guided biopsy, ultrasound-guided biopsy, stereotactic biopsy) and core or fine needle biopsy instruments.

In the United States, biopsy devices represent a mature and high-penetration market. Annual biopsy procedures exceed 5 million, spanning breast, lung, prostate, liver, and other organs. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~ 60 % of growth stems from rising cancer incidence and screening programs.
• Major Market Restraint: ~ 25 % of limitations arise from reimbursement and procedural cost barriers.
• Emerging Trends: ~ 35 % of new device launches include AI-assisted targeting or robotic guidance.
• Regional Leadership: North America commands ~ 35–40 % share of global biopsy device deployment.
• Competitive Landscape: Top 5 global companies share ~ 45 % of device sales in biopsy devices.
• Market Segmentation: Imaging-guided biopsy systems currently account for ~ 30 % of market value.
• Recent Development: ~ 20 % of new systems launched during 2023–2025 integrate real-time navigation and sensor feedback.

Biopsy Devices Market Latest Trends

In recent years, Biopsy Devices Market Trends highlight a shift toward smarter, minimally invasive, and automated biopsy workflows. AI-assisted lesion targeting tools now form ~ 25–35 % of new imaging guidance software modules, improving sampling accuracy by 10–15 %. Robotic biopsy arms with sub-millimeter motion control are installed in ~ 10 % of major cancer centers. Fusion imaging (MRI-US, PET-CT) is used in about 30 % of prostate and liver biopsies.

Biopsy Devices Market Dynamics

The Biopsy Devices Market Dynamics reflect a strong interplay of clinical, technological, and demographic factors shaping demand across developed and emerging economies. Over 20 million biopsy procedures are performed globally each year, driven by early cancer detection, chronic disease management, and minimally invasive diagnostic demand.

DRIVER

"Increasing cancer incidence, preventive screening, and shift toward minimally invasive diagnosis."

Worldwide, over 19 million new cancer cases are diagnosed annually, escalating demand for biopsy devices. Screening programs in breast, lung, and prostate cancers drive adoption of biopsy tools. The rising prevalence of chronic disease and expanded imaging capacity lead to more incidental lesions requiring tissue diagnosis.

RESTRAINT

"High procedural cost, reimbursement constraints, and regulatory complexity."

Advanced biopsy systems (robotic, navigated, sensor-augmented) often incur up to 20–40 % higher cost than conventional devices. In many markets, insurance or health systems reimburse only core needle biopsy consumables, not guidance systems.

OPPORTUNITY

Expansion into emerging regions, integration of AI and robotic biopsy, and personalized diagnostics.

Emerging economies in Asia, Latin America, and MEA currently represent < 20 % of biopsy device adoption but exhibit annual growth rates exceeding 10 %. There is opportunity to deploy lower-cost imaging-guided biopsy solutions in underserved areas.

CHALLENGE

"Validation, procedural consistency, reimbursement alignment, and clinician adoption."

Demonstrating consistent performance across diverse anatomies and lesion types demands large clinical trials. Variability in biopsy sampling quality, false-negative rates (~ 5–10 %), and procedure complications (bleeding, pneumothorax risk ~ 1–3 %) challenge adoption.

Biopsy Devices Market Segmentation

The Biopsy Devices Market Segmentation divides by type—MRI-guided biopsy, ultrasound-guided biopsy, stereotactic-guided biopsy—and application—diagnostic & imaging centers, hospitals, others. MRI-guided biopsy systems are typically deployed in ~ 15 % of advanced centers, favored for prostate and breast lesions.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

MRI-guided Biopsy: MRI-guided biopsy systems are used for high-contrast soft tissue imaging and targeting of lesions not visible via other modalities. They account for ~ 15 % of high-end device deployments. Many prostate, breast, and brain biopsies use MRI guidance due to superior soft tissue differentiation. MRI-guided systems often incorporate robotic needle drives and fusion software with real-time feedback.

The MRI-guided biopsy segment is projected to reach approximately USD 328.67 million in 2025, representing ~15.0 % of the global USD 2,191.1 million biopsy devices market, supported by increasing adoption of precision diagnostics, growing integration of real-time MRI imaging systems, and rising demand for accurate tumor localization and minimally invasive cancer diagnostics across major healthcare facilities worldwide, expanding at a 6.52 % CAGR through 2034.

Top 5 Major Dominant Countries in the MRI-guided Biopsy Segment

• United States: The United States dominates the MRI-guided biopsy segment with an estimated USD 120 million valuation, accounting for ~36.5 % of global share, driven by more than 600,000 MRI-based diagnostic procedures annually.
• Germany: Germany holds a market value of approximately USD 45 million, contributing ~13.7 % of global share, supported by over 350 diagnostic centers equipped with MRI-guided biopsy systems, high public healthcare investment.
• Japan: Japan’s MRI-guided biopsy market stands at nearly USD 40 million, representing ~12.2 % share globally, bolstered by advanced hospital infrastructure, the availability of over 900 MRI scanners nationwide.
• China: China commands a significant position with an estimated USD 30 million, or ~9.1 % of the global MRI-guided biopsy share, supported by rising oncology screening rates, rapid installation of high-field MRI systems across Tier-1 hospitals, and government initiatives promoting early cancer detection, advancing robustly at approximately ~6.8 % CAGR through 2034.
• United Kingdom: The United Kingdom records a market size of roughly USD 20 million, comprising ~6.1 % of total global share, driven by the implementation of national cancer screening programs, increased MRI accessibility across 250+ NHS hospitals, and integration of robotic biopsy assistance systems, expanding moderately at ~6.4 % CAGR throughout the forecast period.

Ultrasound-guided Biopsy: Ultrasound-guided biopsy is the most widely adopted technique, comprising ~ 50 % of total biopsy device usage globally. It is versatile, real-time, cost-effective, and portable. It is employed in breast, thyroid, liver, kidney, and soft tissue biopsies. Many ultrasound systems incorporate needle tracking and Doppler guidance.

The Ultrasound-guided Biopsy Segment is projected to reach approximately USD 1,095.55 million in 2025, accounting for nearly ~50.0 % of the total USD 2,191.1 million global biopsy devices market.

Top 5 Major Dominant Countries in the Ultrasound-guided Biopsy Segment

• United States: The United States leads the ultrasound-guided biopsy market with an estimated USD 430 million, capturing approximately ~39.3 % of the global segment share. This leadership is driven by the presence of over 1,500 diagnostic imaging centers offering ultrasound-guided procedures, the rising incidence of breast and thyroid cancers exceeding 1.2 million annual cases, and continuous advancements in handheld ultrasound technologies, maintaining stable growth near ~6.3 % CAGR.
• China: China’s ultrasound-guided biopsy market stands at approximately USD 200 million, representing ~18.3 % of the global share. Growth is accelerated by the installation of more than 5,000 new ultrasound scanners annually, government-led health reforms expanding rural diagnostic access, and increasing hospital adoption of hybrid ultrasound-imaging platforms, contributing to a robust expansion trajectory of ~7.0 % CAGR over the forecast timeline.
• Japan: Japan holds an estimated market valuation of USD 110 million, contributing around ~10.0 % of the global ultrasound-guided biopsy segment. The country’s growth is supported by its aging population — with over 28 % aged above 65 — rising cancer screening programs, and the availability of AI-integrated ultrasound equipment across 450 major hospitals, sustaining growth at ~6.5 % CAGR through 2034.
• Germany: Germany’s ultrasound-guided biopsy market is valued at nearly USD 90 million, accounting for ~8.2 % of the total global share. The segment’s progress is backed by widespread hospital usage, integration of high-resolution Doppler imaging, and a 20 % increase in outpatient diagnostic procedures across radiology clinics since 2022, maintaining a steady ~6.7 % CAGR throughout the forecast period.
• India: India’s ultrasound-guided biopsy market is projected to reach approximately USD 70 million, equating to ~6.4 % of global share. Growth is primarily driven by healthcare infrastructure expansion in Tier-2 and Tier-3 cities, an estimated 15 % annual rise in breast and liver biopsy procedures, and domestic manufacturing of low-cost biopsy needles, growing dynamically at ~7.1 % CAGR during 2025–2034.

Stereotactic-guided Biopsy: Stereotactic-guided biopsy is widely used in breast tissue sampling under mammography or tomosynthesis guidance. It accounts for ~ 25 % of biopsy device sales in breast oncology specialty centers. Systems use digital mammography or tomosynthesis to pinpoint lesion coordinates and guide biopsy needles with high accuracy.

The Stereotactic-guided Biopsy Segment is projected to be valued at approximately USD 436.78 million in 2025, accounting for ~20.0 % of the global USD 2,191.1 million biopsy devices market, reflecting its crucial role in precise tissue localization within complex anatomical structures.

Top 5 Major Dominant Countries in the Stereotactic-guided Biopsy Segment

• United States: The United States leads the stereotactic-guided biopsy market with an estimated USD 160 million, representing ~36.7 % of the global share. Growth is driven by over 900 certified oncology imaging centers, rising breast cancer prevalence exceeding 280,000 new cases annually, and extensive usage of digital mammography-assisted biopsy systems, maintaining a consistent ~6.3 % CAGR throughout the forecast period.
• Germany: Germany holds a strong position with approximately USD 60 million, accounting for ~13.7 % of the global market. The nation’s dominance stems from a robust network of over 400 specialized oncology hospitals, government-subsidized cancer screening initiatives, and the integration of stereotactic navigation software into radiology systems, growing steadily at ~6.7 % CAGR through 2034.
• United Kingdom: The United Kingdom’s stereotactic-guided biopsy market is valued near USD 45 million, representing ~10.3 % of global share. The country’s expansion is supported by NHS-funded diagnostic upgrades, the deployment of 200+ 3D biopsy units, and the adoption of image-fusion technologies for enhanced lesion targeting, progressing at ~6.4 % CAGR during the assessment period.
• Japan: Japan contributes roughly USD 40 million, or ~9.2 % of the global stereotactic-guided biopsy market, with demand propelled by high-precision oncology procedures, an increasing geriatric population exceeding 36 million, and the integration of computer-assisted biopsy units across major medical centers, ensuring sustained growth at ~6.5 % CAGR.
• France: France captures an estimated USD 30 million, holding ~6.9 % of global market share, supported by widespread adoption of stereotactic biopsy in breast cancer detection, growing investments in digital imaging infrastructure across 250+ public hospitals, and continuous equipment modernization, maintaining moderate expansion at ~6.5 % CAGR through the forecast period.

BY APPLICATION

Diagnostic & Imaging Centers: Diagnostic & imaging centers (standalone radiology / breast imaging clinics) account for ~ 40 % of biopsy device usage. These centers perform lesion localization, core biopsies, and image-guided sampling, often using ultrasound and stereotactic systems. They serve high throughput screening populations, performing thousands of biopsies per year.

The Diagnostic & Imaging Centers segment is forecasted to reach approximately USD 695.33 million in 2025, representing ~31.8 % of the total USD 2,191.1 million Biopsy Devices Market, driven by the proliferation of early cancer screening programs and increasing demand for imaging-guided minimally invasive diagnostic procedures.

Top 5 Major Dominant Countries in the Diagnostic & Imaging Centers Application

• United States: The United States leads with an estimated USD 260 million, capturing approximately ~37.4 % of this segment. Growth is propelled by over 3,500 imaging-based diagnostic facilities, increasing mammography volumes exceeding 40 million annual screenings, and a strong network of accredited radiology centers offering advanced biopsy imaging, expanding steadily at ~6.3 % CAGR.
• Germany: Germany’s Diagnostic & Imaging Centers segment stands at approximately USD 80 million, accounting for ~11.5 % of the global share, fueled by early cancer detection policies, the presence of 250+ advanced radiology hospitals, and integration of digital biopsy tracking systems, achieving consistent growth near ~6.7 % CAGR.
• Japan: Japan contributes roughly USD 70 million, or ~10.1 % of the global share, driven by more than 600 imaging clinics adopting AI-assisted biopsy imaging, growing use in liver and prostate cancer diagnostics, and increased geriatric screening rates, advancing at ~6.5 % CAGR.
• China: China’s Diagnostic & Imaging Centers market is valued at approximately USD 60 million, representing ~8.6 % of the total share, driven by a 25 % rise in cancer screening programs, government-led diagnostic infrastructure expansion, and rural access initiatives, expanding strongly at ~7.0 % CAGR.
• United Kingdom: The United Kingdom records an estimated USD 40 million, or ~5.7 % global share, supported by national diagnostic modernization, NHS expansion of biopsy screening units, and increasing adoption of ultrasound-guided breast biopsy systems, maintaining steady growth around ~6.4 % CAGR.

Hospitals: Hospitals represent ~ 50 % of biopsy device utilization. Inpatient and outpatient departments—such as radiology, oncology, urology, interventional suites—perform biopsies across multiple organs (lung, liver, kidney, brain). They often deploy full imaging + navigation systems (MRI, CT, ultrasound) and purchase entire biopsy suites.

The Hospital segment represents the largest application sector, valued at approximately USD 1,314.66 million in 2025, accounting for ~60.0 % of the global USD 2,191.1 million Biopsy Devices Market.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: The U.S. hospital-based biopsy market is valued at approximately USD 530 million, or ~40.3 % of global share, driven by over 6,000 hospital installations, growing preference for real-time MRI fusion biopsy, and expanding cancer diagnosis rates surpassing 1.9 million new cases annually, sustaining ~6.3 % CAGR.
• Germany: Germany holds an estimated USD 150 million, comprising ~11.4 % of global hospital-based biopsy revenue, supported by state-funded oncology programs, over 400 specialized medical centers, and continuous device upgrades enhancing patient safety and precision, advancing at ~6.7 % CAGR.
• Japan: Japan contributes approximately USD 120 million, equating to ~9.1 % of total hospital application share, driven by over 1,000 tertiary care hospitals, significant oncology screening adoption, and the use of biopsy robotics in liver and prostate procedures, maintaining ~6.5 % CAGR.
• China: China’s hospital-based biopsy segment is valued around USD 110 million, representing ~8.4 % of the global total. This growth stems from rapid healthcare expansion, the addition of 500+ oncology units since 2022, and public health initiatives emphasizing early cancer detection, expanding robustly at ~7.0 % CAGR.
• France: France accounts for nearly USD 70 million, or ~5.3 % of the global hospital segment, driven by strong public healthcare funding, modern diagnostic laboratories in over 250 hospitals, and the integration of 3D-guided biopsy systems, advancing at ~6.5 % CAGR.

Others: “Others” includes mobile clinics, specialized oncology centers, outpatient surgery centers, and research institutions, contributing ~ 10 %. These settings often require portable, lightweight biopsy devices and modular systems. Mobile screening units for breast or prostate cancer frequently rely on ultrasound-guided or compact stereotactic biopsy tools.

The Others segment, which includes private clinics, research institutes, and specialized oncology centers, is estimated at USD 180.2 million in 2025, representing ~8.2 % of the total market.

Top 5 Major Dominant Countries in the Others Application

• United States: The U.S. leads with USD 65 million, representing ~36.1 % of the global share, supported by over 200 private diagnostic chains, active participation of research universities, and corporate-backed biopsy trials advancing device innovation, growing at ~6.3 % CAGR.
• Germany: Germany follows with approximately USD 25 million, equating to ~13.9 % share, bolstered by collaboration between 50+ research centers and leading manufacturers, and rapid adoption of pilot biopsy robotics projects, sustaining consistent growth around ~6.7 % CAGR.
• Japan: Japan’s segment is valued near USD 20 million, or ~11.1 % share, driven by advanced oncology research programs, government-funded cancer prevention projects, and private-sector involvement in minimally invasive biopsy device testing, expanding steadily at ~6.5 % CAGR.
• China: China records roughly USD 15 million, representing ~8.3 % of the total share, fueled by research grants for diagnostic innovation, partnerships with foreign biotech firms, and a rise in specialized clinics, growing at ~7.0 % CAGR.
• United Kingdom: The United Kingdom holds USD 12 million, or ~6.7 % share, supported by academic-medical collaborations, National Health Service research frameworks, and localized manufacturing of smart biopsy instruments, maintaining steady expansion around ~6.4 % CAGR.

Regional Outlook for the Biopsy Devices Market

The Biopsy Devices Market Outlook is globally diverse, with adoption levels reflecting variations in healthcare spending, cancer screening policies, and imaging infrastructure. North America leads the global landscape with approximately 35–40 % share of total device installations, followed by Europe at 25–30 %, Asia-Pacific at 25 %, and the Middle East & Africa holding nearly 10 %.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Biopsy Devices Market with ~ 35–40 % share of global device use. U.S. biopsy procedures exceed 5 million annually, with imaging centers, hospitals, and cancer centers heavily investing in advanced biopsy systems. North American facilities use ~ 45 % of global imaging-guided biopsy platforms. The U.S. market also drives ~ 50 % of global R&D in robotic and AI biopsy devices.

In 2025, the North American Biopsy Devices Market is projected to reach approximately USD 900 million, capturing about ~41.1 % of the global USD 2,191.1 million market, supported by the region’s advanced healthcare infrastructure, widespread cancer screening programs, and early adoption of digital and robotic biopsy systems.

North America – Major Dominant Countries in the “Biopsy Devices Market”

• United States: The United States leads the regional biopsy market with an estimated USD 780 million, representing ~86.7 % of North America’s share, driven by over 2,000 oncology clinics, high mammography screening rates exceeding 70 % of the female population, and robust reimbursement frameworks, maintaining steady expansion near ~6.3 % CAGR.
• Canada: Canada’s biopsy devices market stands at approximately USD 50 million, accounting for ~5.6 % of regional share, with growth supported by a 12 % annual rise in breast and lung biopsy procedures, government healthcare digitization programs, and adoption of MRI-guided systems, advancing at ~6.4 % CAGR.
• Mexico: Mexico’s market is valued at USD 40 million, representing ~4.4 % of the regional share, propelled by rising hospital privatization, the expansion of radiology networks, and increasing use of ultrasound-guided systems in oncology diagnostics, growing steadily at ~6.6 % CAGR.
• Brazil (trade link): Brazil contributes approximately USD 20 million, or ~2.2 % of North America’s extended trade network, supported by cross-border medical device imports and partnerships for breast cancer screening programs, maintaining consistent growth at ~6.5 % CAGR.
• Argentina (trade link): Argentina’s market holds around USD 10 million, or ~1.1 % share of the regional total, driven by expanding diagnostic imaging access and increasing collaboration with North American manufacturers, sustaining a stable ~6.4 % CAGR through 2034.

EUROPE

Europe contributes a significant share—approximately 25–30 %—of global biopsy device usage. Leading countries include Germany, U.K., France, Italy, and Spain. Germany performs ~ 500,000 advanced biopsies annually, anchoring equipment procurement across OEMs. The U.K. and France combine for ~ 30 % of European biopsy device sales.

The European Biopsy Devices Market is expected to reach roughly USD 430 million in 2025, representing around ~19.6 % of the global market share.

Europe – Major Dominant Countries in the “Biopsy Devices Market”

• Germany: Germany leads Europe’s biopsy market with approximately USD 110 million, representing ~25.6 % of the regional share, driven by over 400 advanced oncology hospitals, a 30 % increase in MRI-guided biopsy usage since 2020, and national healthcare digitalization, expanding at ~6.7 % CAGR.
• United Kingdom: The U.K. holds an estimated USD 70 million, or ~16.3 % of the regional share, supported by NHS-funded cancer screening initiatives, installation of 200+ image-guided biopsy units, and expansion of outpatient diagnostic centers, maintaining steady growth near ~6.4 % CAGR.
• France: France contributes around USD 60 million, or ~14.0 % of Europe’s market, with growth driven by breast cancer screening programs covering 85 % of eligible women and modernization of biopsy systems in 250+ tertiary hospitals, sustaining ~6.5 % CAGR.
• Italy: Italy’s biopsy devices market is valued at approximately USD 40 million, capturing ~9.3 % of regional share, fueled by the installation of 150 new diagnostic centers and increased use of vacuum-assisted biopsy systems, progressing steadily at ~6.4 % CAGR.
• Spain: Spain holds about USD 30 million, representing ~7.0 % of the region’s market, supported by early detection programs covering 65 % of target populations, rapid public-private collaborations, and high diagnostic equipment penetration, expanding at ~6.5 % CAGR.

ASIA-PACIFIC

Asia-Pacific is the fastest-emerging region in the Biopsy Devices Market, now contributing ~ 25 % of global device installations. China and India jointly account for over 40 % of regional procedural volume, driven by rising cancer screening, hospital expansion, and diagnostics capacity. Japan and South Korea adopt cutting-edge systems early, representing ~ 25 % of regional high-end device use.

The Asia-Pacific Biopsy Devices Market is projected to be valued at approximately USD 350 million in 2025, accounting for ~16.0 % of the global total.

Asia – Major Dominant Countries in the “Biopsy Devices Market”

• China: China leads Asia’s biopsy devices market with an estimated USD 140 million, accounting for ~40.0 % of the regional share, driven by government-led cancer screening programs, the construction of 300 new oncology hospitals, and adoption of robotic biopsy tools, expanding near ~7.0 % CAGR.
• Japan: Japan’s market stands at approximately USD 80 million, representing ~22.9 % of regional share, fueled by high patient volumes, strong technological integration in MRI and ultrasound biopsy, and healthcare modernization in 700+ hospitals, growing steadily at ~6.5 % CAGR.
• India: India contributes around USD 40 million, equating to ~11.4 % of the regional share, with growth supported by 15 % annual increases in cancer diagnosis rates, public oncology programs, and domestic device manufacturing, expanding dynamically at ~7.2 % CAGR.
• South Korea: South Korea’s biopsy market is valued at approximately USD 35 million, or ~10.0 % of the region’s total, supported by rapid medical digitalization, hospital innovation programs, and expanded use of fusion biopsy technology, maintaining steady growth at ~6.6 % CAGR.
• Singapore: Singapore accounts for USD 10 million, representing ~2.9 % of regional share, driven by regional medical tourism, installation of high-precision imaging units in 30+ private hospitals, and government support for precision diagnostics, growing at ~6.5 % CAGR.

MIDDLE EAST & AFRICA

The Middle East & Africa region presently contributes ~ 10 % or less of global biopsy device usage, but potential is high. GCC nations (UAE, Saudi Arabia, Qatar) lead with advanced facilities performing thousands of image-guided biopsies yearly. South Africa and Egypt provide hubs for device importation and regional training. Annual biopsy procedure counts in MEA exceed 200,000 currently.

The Middle East & Africa (MEA) Biopsy Devices Market is projected to reach approximately USD 111 million in 2025, accounting for ~5.1 % of global market share.

Middle East & Africa – Major Dominant Countries in the “Biopsy Devices Market”

• United Arab Emirates: The UAE’s biopsy devices market is valued at approximately USD 40 million, representing ~36.0 % of regional share, driven by hospital automation initiatives, expansion of 15+ new cancer centers, and adoption of power-assisted biopsy devices, growing at ~6.6 % CAGR.
• Saudi Arabia: Saudi Arabia contributes around USD 30 million, or ~27.0 % of MEA share, supported by national healthcare modernization projects, expansion of oncology departments, and procurement of advanced image-guided systems across 100+ hospitals, sustaining ~6.7 % CAGR.
• South Africa: South Africa’s market holds USD 15 million, representing ~13.5 % of the regional total, driven by public-private partnerships, rising diagnostic accessibility, and adoption of ultrasound-guided systems in major hospitals, growing steadily at ~6.5 % CAGR.
• Egypt: Egypt’s biopsy market is valued near USD 15 million, or ~13.5 % of MEA share, supported by oncology research initiatives, modernization of imaging centers, and expansion of foreign medical collaborations, maintaining progress around ~6.5 % CAGR.
• Nigeria: Nigeria’s market accounts for USD 5 million, representing ~4.5 % of regional share, fueled by emerging private diagnostic centers, growing awareness of early cancer detection, and telemedicine integration, expanding dynamically at ~7.0 % CAGR.

List of Top Biopsy Devices Companies

• Becton, Dickinson and Company
• General Electric Co.
• Carestream Health Inc.
• Scion Medical Technologies LLC
• Hologic Inc.
• Argon Medical Devices Inc.
• Danaher Corporation
• Dickinson and Co.
• Planmed Oy
• FUJIFILM Holdings Corporation
• Siemens Healthineers AG

Becton, Dickinson and Company: Becton, Dickinson accounts for approximately 18.5 % of the global biopsy devices market, operating in over 190 countries, with more than 65 manufacturing facilities and 70 million biopsy units distributed annually worldwide.

Hologic Inc.: Hologic represents nearly 12.3 % of the global biopsy devices market share, supplying advanced vacuum-assisted breast biopsy systems to over 10,000 hospitals and diagnostic centers across 80 countries, with over 35 patented imaging solutions.

Investment Analysis and Opportunities

Investment in the Biopsy Devices Market is focused on integrating imaging, robotics, AI, and sensor feedback to increase precision and throughput. OEMs allocate ~ USD 200–300 million annually in R&D, with ~ 40 % of that budget targeting AI-assisted targeting, robotic automation, and navigation software. Emerging markets—particularly in Asia and Latin America—offer opportunity; device penetration in many developing countries remains below 10 % of per capita need.

New Product Development

Leading device firms and innovators are launching advanced biopsy systems integrating robotics, AI, sensor feedback, and multi-modal imaging. Robotic biopsy platforms with sub-millimeter needle control and motion compensation for breathing and organ motion are now installed in over 50 high-volume cancer centers. AI-augmented targeting modules use lesion segmentation and predicted needle paths, improving targeting accuracy by ~ 10 %.

Five Recent Developments

• A major vendor launched a robotic biopsy platform enabling automated needle positioning and sampling in deep organs, improving targeting success by ~15 %.
• Developers introduced single-use, disposable core biopsy needles; adoption climbed ~12 % in hospitals to reduce cross-contamination and sterilization burdens.
• An imaging-guided vacuum-assisted breast biopsy system was installed in over 100 clinics, enabling removal of up to 20 mm lesions in a single sample.
• A new AI-augmented biopsy guidance software was integrated with MRI fusion tools in over 70 diagnostic centers to enhance lesion localization accuracy by ~10 %.
• Expansion of portable ultrasound biopsy probes occurred across 50 ambulatory centers, cutting procedure times by ~20 % and extending access in underserved regions.

Report Coverage of Biopsy Devices Market

The Biopsy Devices Market Report offers comprehensive coverage from 2020 through 2025 historical data and forecasts up to 2034. The scope includes segmentation by type (MRI-guided biopsy, ultrasound-guided biopsy, stereotactic biopsy) and by application (diagnostic & imaging centers, hospitals, others). End-user settings and adoption behavior are explored across regions.

Biopsy Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 2333.96 Million in 2026
Market Size Value By	USD 4121.47 Million by 2035
Growth Rate	CAGR of 6.52% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : MRI?guided Biopsy Ultrasound?guided Biopsy Stereotactic?guided Biopsy By Application : Diagnostic & Imaging Centers Hospitals Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample